Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis

Mucopolysaccharidosis type I (MPS I) is an autosomal recessive disease caused by deficient activity of alpha-L-iduronidase. Intravenous (IV) enzyme replacement therapy (ERT) with laronidase is currently used for treating patients with MPS I. OBJECTIVE: To evaluate the efficacy and safety of IV laron...

Descripción completa

Detalles Bibliográficos
Autores principales: Dornelles, Alícia Dorneles, Artigalás, Osvaldo, da Silva, André Anjos, Ardila, Dora Lucia Vallejo, Alegra, Taciane, Pereira, Tiago Veiga, Vairo, Filippo Pinto e, Schwartz, Ida Vanessa Doederlein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578671/
https://www.ncbi.nlm.nih.gov/pubmed/28859139
http://dx.doi.org/10.1371/journal.pone.0184065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578671/
https://www.ncbi.nlm.nih.gov/pubmed/28859139
http://dx.doi.org/10.1371/journal.pone.0184065

Ejemplares similares